- Trial phase
- Approved / marketed
- Time to market
- Already on the market, FDA approved May 20, 2011 (adults); pediatric formulation (EDURANT PED) approved March 15, 2024.
- Why 3/10
- No hard, dated regulatory catalyst for EDURANT in the next ~12 months, the drug was approved in 2011 (adult) and 2024 (pediatric), and the only near-term dated item is primary completion (2026-08-18) of a 48-patient Phase 2 pediatric roll-over safety study (NCT02494986), which is not a commercial binary, so the score sits at the low end of the approved-product band.
For a JNJ investor, EDURANT is immaterial to the thesis: it is a mature, already-approved HIV pill inside a mega-cap whose value is set by far larger franchises (per JNJ's 10-Q/earnings filings), and no pivotal or regulatory binary is scheduled for this molecule. The only scheduled item to watch is primary completion of the pediatric roll-over study (NCT02494986, est. 2026-08-18); treat any news around it as routine label-support data, not a re-rating event. The more interesting rilpivirine exposure is the long-acting injectable space (cabotegravir + rilpivirine) being developed with ViiV/GSK, but that is a GSK-led program (NCT05917509, Phase 3, completed 2026-04-20), not a JNJ-only catalyst.
Price Chart
Executive Summary
EDURANT is Johnson & Johnson's (Janssen) rilpivirine HIV tablet, first FDA-approved May 20, 2011, with the pediatric version (EDURANT PED) approved March 15, 2024, per SecBot's FDA catalyst records. It is a mature, marketed product with no pending approval decision or pivotal readout; ongoing JNJ activity is a small Phase 2 pediatric roll-over study (NCT02494986) whose estimated primary-completion date is 2026-08-18. A routine FDA safety-labeling update was recorded March 5, 2026 for the emtricitabine/rilpivirine/tenofovir combination product (hepatitis B exacerbation warning). For JNJ ($262.37 close 2026-08-17; mean analyst PT $272.50 across 22 analysts), EDURANT is a small part of a large portfolio and not a share-price driver.
How It Works
EDURANT (rilpivirine) is a once-daily oral pill for HIV-1. It blocks an enzyme the virus needs to copy its genetic material (reverse transcriptase), so the virus cannot multiply as easily; it is always taken as part of a combination regimen with other antiretrovirals, with food. Rilpivirine is also a component of fixed-dose combination pills and of long-acting injectable regimens used with other HIV drugs.
Trial Status
EDURANT is approved and commercialized. Ongoing JNJ-sponsored work is limited to label-support: a Phase 2 pediatric roll-over study (NCT02494986, Janssen Sciences Ireland UC, 48 patients, active-not-recruiting, est. primary completion 2026-08-18, est. completion 2027-06-30). Separately, a ViiV/GSK-sponsored Phase 3 study of long-acting injectable cabotegravir + rilpivirine every two months versus oral DTG/3TC (NCT05917509, 171 patients) was completed (primary completion 2025-09-16, completion 2026-04-20), relevant to rilpivirine's long-acting future but led by GSK, not JNJ.
The Two-Sided Case
Upcoming Catalysts
- Estimated primary completion (2026-08-18) of Phase 2 pediatric roll-over study NCT02494986, routine safety/continuation data in 48 patients, not a commercial binary.
- No PDUFA, advisory-committee, or pivotal readout dates are recorded for EDURANT in the next 12 months.
- Watch GSK-led long-acting injectable (cabotegravir + rilpivirine) commercialization news as the main way rilpivirine exposure could matter, via ViiV, not JNJ.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
JOHNSON & JOHNSON 8-K JNJ ·Originating report